MarketPeel
Insider Trading Intelligence
Pricing
…
RR

Rene Russo

XLO
CEO AND PRESIDENT · XILIO THERAPEUTICS, INC. · CIK 0001722066
FILING MIX · LIFETIME71%/29%
BUYS
25
SELLS
10
TOTAL VALUE
$81.7K
COMPANIES
2
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
94,500
AVG SELL PX
—
TRADE KIND
SHOWING 35 / 35
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Rene Russo, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-2.33%-0.42%-1.91%-1.91%—
14d1+0.00%-0.88%+2.52%-3.39%-3.39%—
30d1+100.00%+6.41%+3.57%+2.84%+2.84%—
60d1+100.00%+3.35%+6.76%-3.41%-3.41%—
90d1+100.00%+9.62%+9.66%-0.04%-0.04%—
180d1+0.00%-0.73%+13.12%-13.85%-13.85%—
1y1+0.00%-16.98%+25.25%-42.23%-42.23%—
2y1(1 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XLO · 88,500 shares · as of Jan 1, 2026
0518,7501,037,5001,556,2502,075,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 25 buys / 10 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
PRESIDENT AND CEO
44,250——325,422Jan 1, 2026Jan 5, 2026 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
44,250——88,500Jan 1, 2026Jan 5, 2026 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,500,258——1,500,258Dec 31, 2025Jan 5, 2026 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
350,000——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
473,334——473,334Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,075,000——2,075,000Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
350,000——350,000Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
239,703——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
473,334——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
135,134——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
700,000——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
239,703——239,703Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
135,134——135,134Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
100,000——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
150,000——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,041——50,041Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
700,000——700,000Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
50,041——0Nov 21, 2025Nov 25, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
PRESIDENT AND CEO
36,289$0.68$24.7K281,172Jun 16, 2025Jun 18, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
190,000——190,000Apr 15, 2025Apr 16, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
PRESIDENT AND CEO
44,250——244,883Jan 1, 2025Jan 3, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
SALE
PRESIDENT AND CEO
44,250——132,750Jan 1, 2025Jan 3, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
638,000——638,000Jan 1, 2025Jan 3, 2025 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
474,000——474,000May 1, 2024May 3, 2024 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
177,000——177,000Jan 1, 2024Jan 3, 2024 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
700,000——700,000Aug 16, 2023Aug 18, 2023 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
350,000——350,000Jan 1, 2023Jan 4, 2023 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Feb 22, 2022Feb 24, 2022 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Dec 22, 2021Jan 4, 2022 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Dec 22, 2021Dec 23, 2021 ↗View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,041——50,041Oct 21, 2021Oct 25, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
6,000$9.50$57.0K6,000Jun 2, 2021Jun 2, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
3,427——3,427Jun 10, 2020Jun 11, 2020 ↗View →
Other insiders · XLO
Loading peer insiders…
About this filer
CIK 0001722066
ROLE
CEO AND PRESIDENT
PRIMARY
XLO
COMPANIES
2
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001722066DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback